In the phase I study of CheckMate 032, it was reported that lutathera combined with nivolumab showed some antitumor activity, suggesting that the strong uptake of 68Gallium-DOTATATE may predict efficacy of combining lutathera with anti-PD-L1 therapy in SCLC patients [27]. The gene discussed is CD274; the disease is small cell lung carcinoma.